The natural course of progressive systemic sclerosis patients with interstitial lung involvement

Clinical Rheumatology

Volumn 26, Issue 3, 2007, Pages 349-354

  Benan, Musellim ^a   Hande, Ikitimur ^a,b   Gul, Ongen ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Adnan Kahveci Bulvarý Rontgen sokak ^*  (Turkey)

Author keywords

Interstitial lung involvement; Natural course; Systemic sclerosis

Indexed keywords

COLCHICINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; STEROID;

ADULT; AGED; ARTHROPATHY; ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SKIN DISEASE; SYSTEMIC SCLEROSIS;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, DIFFUSE;

EID: 33947697880     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0302-6     Document Type: Article

References (45)

1. Black CM, Stephens SC (1993) Systemic sclerosis (scleroderma) and related disorders. In: Maddison PJ, Isenberg DA, Woo P, Glass DN (eds) Oxford textbook of rheumatology. Oxford University Press, Oxford, pp 771-789
2. Medsger TA (1993) Systemic sclerosis (scleroderma), localized scleroderma, eosinophilic fasciitis and calcinosis. In: McCarty DJ, Koopman WJ (eds) Arthritis and allied conditions, 12th edn. Lea and Febiger, Philadelphia, pp 1113-1143
3. Seibold JR (1997) Scleroderma. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (eds) Textbook of rheumatology, 5th edn. Saunders, Philadelphia, pp 1133-1163
4. Le Roy EC (1996) Systemic sclerosis (scleroderma). In: Bennet SC, Plumm F, Glass DN (eds) Cecil' s textbook of medicine. Saunders, Philadelphia, pp 1183-1188
5. Wigley MF (1998) Systemic sclerosis. In: Klippel JK, Dieppe PA (eds) Rheumatology. Mosby, St Louis, pp 79.1-79.14
6. Veale DJ, Collidge TA, Belch JJ (1995) Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 54:853-855
7. Silman A, Jannini S, Symmons D et al (1988) An epidemiologic study of scleroderma in West Midlands. Br J Rheumatol 27(4):286-290
8. Geirsson AJ, Steinsson K, Guthmundsson S et al (1994) Systemic sclerosis in Iceland. A nationwide epidemiologic study. Ann Rheum Dis 53(8):502-505
9. Roberts-Thomson PJ, Jones M, Hakendorf P et al (2001) Scleroderma in South Australia: Epidemiological observations of possible pathogenic significance. Intern Med J 31(4):220-229
10. Steen VD, Oddis CV, Conte CG et al (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum 40(3):441-445
11. Mayes M, Laing T, Gillespie B et al (1996) Prevalence, incidence and survival rates of systemic sclerosis in the Detroit Metropolitan Area. Arthritis Rheum 39:S150, (Suppl)
12. Rossa AD, Valentini G, Bombardieri S et al (2001) European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 60:585-591
13. Coghlan JG, Mukerjee D (2001) The heart and pulmonary vasculature in scleroderma: Clinical features and pathobiology. Curr Opin Rheumatol 13(6):495-499
14. Garber SJ, Wells AU, duBois RM et al (1992) Enlarged mediastinal lymph nodes in the fibrosing alveolitis of systemic sclerosis. Br J Radiol 65(779):983-986
15. Schurawitzki H, Stiglbauer R, Granibger W et al (1990) Interstitial lung disease in progressive systemic sclerosis: High-resolution CT versus radiography. Radiology 176(3):755-759
16. Griedinger EL, Flaherty KT, White B et al (1998) African American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 114:801-807
17. Steen VD, Conte C, Owens GR et al (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283-1289
18. Steen VD, Medsger JR TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43(11):2437-2444
19. Shuford WH, Seaman WB, Goldman A (1953) Pulmonary manifestations of scleroderma. Arch Intern Med 92:85-97
20. Weaver AL, Divertie MB, Titus JL (1987) The lung in scleroderma. Mayo Clin Proc 42:754-766
21. Spain DM, Thomas AG (1950) The pulmonary manifestations of scleroderma: an anatomic-physiologic correlation. Ann Intern Med 32:152-161
22. Rodnan GP (1963) The natural history of progressive systemic sclerosis (diffuse scleroderma). Bull Rheum Dis 13:301-304
23. Antony TH, Lin MD, Philip J et al (2003) Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am 29:409-426
24. White B (2003) Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 29:371-390
25. Subcomittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(3):581-586
26. Bluestone R, Grahame R, Holloway V et al (1970) Treatment of systemic sclerosis with d -penisillamine. A new method of observing the effects of treatment. Ann Rheum Dis 29:153-158
27. Steen VD, Medsger TA, Rodnan GP (1982) d -Penisillamine therapy in progressive systemic sclerosis (scleroderma): A retrospective analysis. Ann Intern Med 97:652-659
28. Jimenez SA, Sigal SH (1991) A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with d - penisillamine. J Rheumatol 18:1496-1503
29. Kang B, Veres-Thorner C, Heredia R et al (1982) Successful treatment of far-advanced progressive systemic sclerosis by d -penicillamine. J Allergy Clin Immunol 69:279-305
30. Steen VD, Owens GR, Redmond C et al (1985) The effect of d -penisillamine on pulmonary findings in progressive systemic sclerosis. Arthritis Rheum 28:882-888
31. DeClerck LS, Dequeker J, Francx L, Demedts M (1987) d-Penicillamine therapy and interstitial lung disease in scleroderma. Arthritis Rheum 30(6):643-650
32. Thomson J, Milne JA (1974) Two years of penicillamine for progressive syclerosis: A case report. Postgrad Med J 5:36-38
33. Smiley JD, Johnson RL Jr, Ziff M (1967) Effect of d-penicillamine on pulmonary function in patients with progressive systemic sclerosis (abstract). Arthritis Rheum 10:313-314
34. Clements PJ, Furst DE, Wong WK et al (1999) High-dose versus low-dose d-penisillamine in early diffuse systemic sclerosis analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194-1203
35. Rodnan GP, Black RL, Bollet AJ, Bünim JJ (1956) Observations on the use of prednisone in patients with progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med 44:16-29
36. Van den Hoogen FH, Boerbooms AM, Van de Putte LB et al (1989) Methotrexate treatment in scleroderma. Am J Med 87:116-117
37. Van den Hoogen FH, Boerbooms AM, Van de Putte LB et al (1991) Low dose methotrexate treatment in systemic sclerosis [letter]. J Rheumatol 18:1763-1764
38. Van den Hoogen FH, Boerbooms AM, Swaak AJ et al (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 35:364-372
39. Pope JE, Bellamy N, Seibold JR et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351-1358
40. Silver RM, Warrick JH, Kinsella MB et al (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838-844
41. Akesson A, Scheja A, Lundin A et al (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729-735
42. Steen VD, Lanz KJ, Conte C et al (1994) Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37:1290-1296
43. Davas E, Peppas C, Maragou M et al (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:458-461
44. Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) Randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25(2):205-212
45. White B, Moore WC, Wigley FM et al (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947-954